Viracta Therapeutics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | - | 3.5m | 19.4m |
| % growth | - | - | - | - | - | - | 453 % |
| EBITDA | (18.8m) | 62.7m | (50.6m) | (46.9m) | - | - | - |
| Profit | (19.0m) | (115m) | (49.2m) | (51.1m) | (38.1m) | (45.2m) | (36.2m) |
| % profit margin | - | - | - | - | - | (1292 %) | (187 %) |
| EV / revenue | - | - | - | - | - | 2.4x | 0.4x |
| EV / EBITDA | - | 0.6x | -1.1x | -0.5x | - | - | - |
| R&D budget | 13.5m | 23.9m | 26.3m | 33.4m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$18.4m | Series B | ||
$10.0m | Early VC | ||
N/A | Series D | ||
| N/A | N/A | IPO | |
$65.0m | Private Placement VC | ||
$50.0m | Post IPO Debt | ||
| Total Funding | €84.9m | ||
Recent News about Viracta Therapeutics
EditViracta Therapeutics is a precision oncology company focused on developing innovative therapies for virus-associated malignancies, such as Epstein-Barr Virus (EBV) associated lymphomas. The company operates in the biotechnology and pharmaceutical market, primarily serving patients with viral-associated cancers and other serious diseases. Viracta's business model revolves around the research, development, and commercialization of targeted treatments. The company generates revenue through the sale of its proprietary drugs and potential licensing agreements with other pharmaceutical companies. By leveraging its expertise in oncology and virology, Viracta aims to address unmet medical needs and improve patient outcomes.
Keywords: precision oncology, virus-associated malignancies, EBV, lymphomas, biotechnology, pharmaceutical, targeted treatments, innovative therapies, patient outcomes, virology.
